Latest Breaking News On - Cardurion pharmaceuticals inc - Page 1 : comparemela.com

Form 424B3 NewAmsterdam Pharma Co

Imara Inc. (IMRA) enters Asset Purchase Agreement with Cardurion Pharmaceuticals providing for sale of tovinontrine

Mintz Venture Watch — Volume 2: A Report On Deal Trends From Q3 And Q4 2021 - Corporate/Commercial Law

The second half of 2021 continued to show strong venture investing activity across a wide range of sectors. Technology and Life Science transactions were the dominant force in the 65+ deals the.

Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine

Share: Appointment reflects progress of Company s early-stage pipeline toward the clinic Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer and head, translational medicine. Dr. Surks joins Cardurion from Sanofi where he most recently served as head, translational medicine and clinical pharmacology U.S. We are very gratified that Howard has decided to join the Cardurion team at a time when our early-stage pipeline is moving rapidly toward the clinic, said Peter Lawrence, chief executive officer of Cardurion. Howard s decades-long leadership encompassing cardiovascular drug discovery and development at Sanofi and Merck, and his basic cardiovascular research experience at Tufts Medical Center and School of Medicine